Opaleye Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Opaleye Management’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-654,943	Closed	-$1.41M	–	49
2024 Q3	$1.41M	Sell	654,943 -210,500	-24%	-$756K	0.23%	40
2024 Q2	$4.47M	Buy	865,443 +77,898	+10%	+$409K	1.02%	29
2024 Q1	$4.21M	Buy	787,545 +428,175	+119%	+$2.96M	0.92%	29
2023 Q4	$2.8M	Buy	+359,370	New	+$1.23M	0.74%	34
2018 Q2	–	Sell	-7,407	Closed	-$961K	–	42
2018 Q1	$961K	Hold	7,407	–	–	0.27%	35
2017 Q4	$720K	Sell	7,407 -4,250	-36%	-$571K	0.23%	33
2017 Q3	$1.72M	Buy	11,657 +707	+6%	+$133K	0.61%	30
2017 Q2	$1.76M	Buy	10,950 +8,435	+335%	+$1.33M	0.74%	31
2017 Q1	$400K	Buy	+2,515	New	+$307K	0.2%	42

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Opaleye Management's SYRS Position: Q4 2024 in Review

Opaleye Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2024, closing a stake of 654,943 shares — an estimated $1.41M sold.

Opaleye Management first reported a position in SYRS in Q1 2017 and held it in 9 quarters. The position peaked at $4.47M in Q2 2024. 44 funds tracked by Wall St. Rank hold SYRS as of Q4 2024.

Opaleye Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Opaleye Management sold 654,943 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $1.41M.
Opaleye Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q1 2017 and held it in 9 quarters.
Opaleye Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $4.47M in Q2 2024.
44 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on Opaleye Management's 13F filing for Q4 2024, filed 14 Feb 2025.